Rosa & Co. to Present Research Results With a Poster at the 4th World Parkinson Congress (WPC)

Tuesday, September 13, 2016 Research News
Email Print This Page Comment bookmark
Font : A-A+

SAN CARLOS, Calif., Sept. 13, 2016 /PRNewswire/ -- Rosa & Co. LLC, the leading commercial drug development advisory

firm with expertise in quantitative biological PhysioPD™ modeling, today announced their participation and poster presentation at the 4th World Parkinson Congress  to be held in Portland, Oregon
on September 20–23, 2016.  The conference will provide an international forum for dialogue on the latest scientific discoveries, medical practices, and caregiver initiatives related to Parkinson's disease.

Logo - 

Dr. Christina Friedrich, Chief Engineer, PhysioPD at Rosa, will present a poster entitled "Development of a qualitative systems pharmacology model to support hypothesis generation and testing for Parkinson's disease" on Friday September 23, 2016 at 11:30am to 1:30pm.  The poster will demonstrate that the research team identified key biological uncertainties and hypotheses and recommended focused laboratory experiments to gain a better understanding of synuclein function in Parkinson's disease.

In recent years, PhysioPD has emerged as a powerful research approach that enables scientific insight and informs decisions from early discovery through clinical development. The most innovative R&D organizations in the industry are increasingly adopting PhysioPD Research as an essential research component for more informed decision-making. Rosa's participation in this international conference further demonstrates its commitment to expanding the adoption of PhysioPD into a standard research method used within the pharmaceutical industry.

"Rosa & Co. is pleased to share the results of our innovative research and that of our clients, and are honored that our submitted presentation was accepted for inclusion in the WPC 2016 meeting." - Dr. Mike Reed, Chief Scientist, PhysioPD, Rosa & Co. LLC

About Rosa Rosa supports clients with their critical decisions – from preclinical through clinical development – by creating and using customized PhysioPD Research Platforms that connect mechanisms to outcomes and are used to research and simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Rosa's clients are involved in Platform creation, testing, and biological simulation research. Clients retain the Platforms as a program asset to support decisions and future research. Rosa's staff has unparalleled professional experience applying biological modeling and simulation research to accelerate drug development and has over 13 years of client engagements in virtually all therapeutic areas. Rosa is unique in its breadth and depth of disease area experience, including metabolic diseases, immuno-oncology, oncology, cardiovascular, inflammation, immune dysfunction, central nervous system disorders, dermatology, and antibacterial/antiviral biology. For more information, visit

Rosa and the Rosa logo are registered trademarks of Rosa & Co. LLC.

Media Contact:Stephanie Sherman425-591-5738Email

To view the original version on PR Newswire, visit:

SOURCE Rosa & Co.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store